Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article (see Recession is Imminent: We Need […]

Silk Road Medical, Inc. (SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic. Silk Road Medical is committed to working closely with its partners as part of the coordinated public and private sector response to this unforeseen event. Protecting the health and wellbeing of employees and others: In line with recommendations from federal and local government and healthcare agencies, Silk Road Medical has transitioned employees, except for those deemed essential to key aspects of the business, to a remote work environment.

SUNNYVALE, Calif., April 30, 2020 -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported.

Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders. The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Silk Road Medical with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on May 5, 2020.

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors responded negatively to the medical device company's pricing of a public stock offering.

Dr. Robert Mittendorff of Norwest Venture Partners took some time from two days of training before his weekend shifts in an ER at a Bay Area hospital to share his insights about the health and economic impact of COVID-19, as well as advice on what startups should be doing.

1,923,076 shares in the offering are being offered for sale by Silk Road Medical, and 4,885,078 shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road are expected to be approximately $75 million.

SUNNYVALE, Calif., Feb. 26, 2020 -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported.

$75 million of the shares in the offering are being offered for sale by Silk Road Medical and $25 million of the shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders expect to grant the underwriters a 30-day option to purchase up to an additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SUNNYVALE, Calif., April 21, 2020 -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV (NASDAQ: CNTG) * Cue Biopharma Inc (NASDAQ: CUE) * Forty Seven Inc (NASDAQ: FTSV) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Molecular Templates Inc (NASDAQ: MTEM) * Natera Inc (NASDAQ: NTRA) * Ocular Therapeutix Inc (NASDAQ: OCUL) (Piper Sandler lifted the price target for the shares from $7 to $11) * Quest Diagnostics Inc (NYSE: DGX) (announced plans to launch a COVID-19 test service) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech stocks that hit 52-week lows March 5.) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP) * Aytu Bioscience Inc (NASDAQ: AYTU) * Celcuity Inc (NASDAQ: CELC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN) * EXACT Sciences Corporation (NASDAQ: EXAS) * Glaukos Corp (NYSE: GKOS) * Lantheus Holdings Inc (NASDAQ: LNTH) * Mylan NV (NASDAQ: MYL) * Neurometrix Inc (NASDAQ: NURO) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG) (went public last week) * Polarityte Inc (NASDAQ: PTE) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) (reacted to first-quarter results) * T2 Biosystems Inc (NASDAQ: TTOO) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus AstraZeneca's Imfinzi Flunks Late-Stage Study In Advanced Bladder Cancer AstraZeneca plc (NYSE: AZN) said a late stage trial that evaluated Imfinzi and Imfinzi plus tremelimumab in unresectable, Stage IV bladder cancer did not meet the primary endpoints of improving overall survival versus standard-of-care chemotherapy for Imfinzi monotherapy in patients whose tumor cells and/or tumor-infiltrating immune cells express high levels of PD-L1, or for Imfinzi plus tremelimumab in patients regardless of their PD-L1 expression.In premarket trading, the shares were slipping 1.65% to $47.58.AbbVie Gets Label Expansion For Shorter-Duration Maviret Course In Hepatitis C AbbVie Inc (NYSE: ABBV) said the European Commission has approved a change to the marketing authorization for Maviret to shorten once-daily treatment duration from 12 weeks to eight weeks in treatment-naive, compensated cirrhotic, chronic hepatitis C patients with genotype 3 infection."A shorter treatment duration means that more patients with HCV can be treated with an 8-week course of MAVIRET in the absence of initial tests to determine their genotype or degree of fibrosis or cirrhosis," Janet Hammond, vice president of generic medicines and the virology therapeutic area at AbbVie, said in a statement. Maviret is a collaboration with Enanta Pharmaceuticals Inc (NASDAQ: ENTA).Neuronetics System Receives Breakthrough Device Designation Neuronetics Inc (NASDAQ: STIM) said the FDA granted Breakthrough Device Designation for its NeuroStar Advanced Therapy System for the treatment of bipolar depression.NeuroStar Advanced Therapy, according to the company, is the market leader in transcranial magnetic stimulation, a non-invasive form of neuromodulation, and has been approved for unipolar major depression.The stock was trading 40.22% higher at $3.80 at the time of publication in Friday's premarket session. Silk Road Medical Shares Uplist To Nasdaq Global Select Market Silk Road Medical Inc (NASDAQ: SILK) said its common stock has been approved for uplisting to the Nasdaq Global Select Market and will continue to trade under its current ticker symbol, "SILK." The company went public in April 2019.Earnings Oncology-focused biopharma Arcus Biosciences' fourth-quarter revenue rose from $1.6 million in 2018 to $9.8 million in 2019. The net loss per share widened from 28 cents to 38 cents, which was narrower than the consensus loss estimate of 51 cents per share. Cash, cash equivalents and investments in marketable securities stood at $188.3 million as of Dec. 31, 2019 compared with $259.7 million as of Dec. 31, 2018.In premarket trading Friday, Arcus shares were rising 4.06% to $20.View more earnings on IBBEnzo Biochem, Inc.'s (NYSE: ENZ) fiscal second-quarter revenue edged up from $19.3 million in 2019 to $19.4 million in 2020. The non-GAAP loss narrowed from 18 cents per share to 12 cents per share.The shares were ripping 50.44% higher to $3.40 in Friday's premarket session. Eton Pharmaceuticals Inc (NASDAQ: ETON) reported revenue of $500,000 and a loss of 15 cents per share for the fourth quarter of 2019 versus no revenue and a loss of $2.24 per share one year ago.Eton shares were advancing 6.12% to $5.90 in premarket trading Friday.BioNano Genomics Inc (NASDAQ: BNGO) reported a decline in its fourth-quarter revenue from $4 million in 2018 to $2.8 million in 2019. The net loss widened from $6.41 million to $7.9 million. As of Dec. 31, 2019, the company had cash and cash equivalents of $17.3 million compared to $16.5 million at the end of fiscal year 2018.In premarket trading Friday, BioNano shares were down 24.78% at 85 cents.On The Radar Earnings * Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open) * Digirad Corporation (NASDAQ: DRAD) (before the market open) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) (before the market open)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors See more from Benzinga * The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

SUNNYVALE, Calif., March 05, 2020 -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact,.

Toronto, Ontario--(Newsfile Corp. - April 26, 2020) - Silk Energy Limited (CSE: SILK) (the "Company") announces that due to delays caused by the COVID-19 crisis, it is relying on the exemption provided in Ontario Instrument 51-502 - Temporary Exemption from Certain Corporate Finance Requirements of the Ontario Securities Commission to postpone the filing of its annual audited financial statements for the year ended December 31, 2019, as required by section 4.2 of National Instrument 51-102 ...

Image source: The Motley Fool. SILK ROAD MEDICAL INC (NASDAQ: SILK)Q1 2020 Earnings CallApr 30, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.

1,923,076 shares in the offering were offered for sale by Silk Road Medical, and 4,885,078 million shares were offered for sale by certain selling securityholders. Gross proceeds from the offering to Silk Road Medical were approximately $75 million. The selling stockholders granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions.

It's been a mediocre week for Silk Road Medical, Inc (NASDAQ:SILK) shareholders, with the stock dropping 15% to...

Silk Road Medical, Inc's (NASDAQ:SILK): Silk Road Medical, Inc. operates as a medical device company in the United...

SUNNYVALE, Calif., April 29, 2020 -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the.

Toronto, Ontario--(Newsfile Corp. - April 27, 2020) - Silk Energy Limited (CSE: SILK) (the "Company") is pleased to report it has entered into revised agreements concerning its interest in the Ustyurt Property and its financing arrangements.BackgroundThe Company's business is to explore for oil and gas on the Ustyurt Property in the Republic of Kazakhstan, through the Company's wholly-owned Norwegian subsidiary, Silk Energy AS ("Silk AS"). The Kazakh government has granted an exploration license to ...